SAB Net Invested Capital from 2010 to 2024

SABSW Stock  USD 0.07  0  5.75%   
SAB Biotherapeutics Net Invested Capital yearly trend continues to be fairly stable with very little volatility. Net Invested Capital will likely drop to about 37 M in 2024. Net Invested Capital is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. View All Fundamentals
 
Net Invested Capital  
First Reported
2010-12-31
Previous Quarter
58.4 M
Current Value
37 M
Quarterly Volatility
21.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check SAB Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SAB Biotherapeutics' main balance sheet or income statement drivers, such as Interest Income of 80.1 K, Depreciation And Amortization of 3.9 M or Interest Expense of 289.4 K, as well as many indicators such as Price To Sales Ratio of 16.12, Dividend Yield of 0.0 or PTB Ratio of 0.7. SAB financial statements analysis is a perfect complement when working with SAB Biotherapeutics Valuation or Volatility modules.
  
Check out the analysis of SAB Biotherapeutics Correlation against competitors.
For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.

Latest SAB Biotherapeutics' Net Invested Capital Growth Pattern

Below is the plot of the Net Invested Capital of SAB Biotherapeutics over the last few years. It is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. SAB Biotherapeutics' Net Invested Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in SAB Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Invested Capital10 Years Trend
Slightly volatile
   Net Invested Capital   
       Timeline  

SAB Net Invested Capital Regression Statistics

Arithmetic Mean13,160,063
Geometric Mean3,103,681
Coefficient Of Variation161.15
Mean Deviation18,694,355
Median(860,703)
Standard Deviation21,206,970
Sample Variance449.7T
Range59.2M
R-Value0.80
Mean Square Error172.2T
R-Squared0.64
Significance0.0003
Slope3,806,740
Total Sum of Squares6296.3T

SAB Net Invested Capital History

202437 M
202358.4 M
202232.4 M
202138.6 M
202039.7 M

About SAB Biotherapeutics Financial Statements

SAB Biotherapeutics investors use historical fundamental indicators, such as SAB Biotherapeutics' Net Invested Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in SAB Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Invested Capital58.4 M37 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for SAB Stock Analysis

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.